IL144851A0 - 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists - Google Patents
3-phenylpyridine derivatives and their use as nk-1 receptor antagonistsInfo
- Publication number
- IL144851A0 IL144851A0 IL14485100A IL14485100A IL144851A0 IL 144851 A0 IL144851 A0 IL 144851A0 IL 14485100 A IL14485100 A IL 14485100A IL 14485100 A IL14485100 A IL 14485100A IL 144851 A0 IL144851 A0 IL 144851A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- phenylpyridine derivatives
- phenylpyridine
- derivatives
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99103503 | 1999-02-24 | ||
PCT/EP2000/001223 WO2000050401A1 (en) | 1999-02-24 | 2000-02-15 | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL144851A0 true IL144851A0 (en) | 2002-06-30 |
Family
ID=8237624
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14485100A IL144851A0 (en) | 1999-02-24 | 2000-02-15 | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
IL144851A IL144851A (en) | 1999-02-24 | 2001-08-09 | Derivatives of 3-phenylpyridine and their use as NK-1 receptor antagonists |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL144851A IL144851A (en) | 1999-02-24 | 2001-08-09 | Derivatives of 3-phenylpyridine and their use as NK-1 receptor antagonists |
Country Status (33)
Country | Link |
---|---|
US (1) | US6225316B1 (xx) |
EP (1) | EP1157005B1 (xx) |
JP (1) | JP4068305B2 (xx) |
KR (1) | KR100437587B1 (xx) |
CN (1) | CN1134417C (xx) |
AR (1) | AR029616A1 (xx) |
AT (1) | ATE280158T1 (xx) |
AU (1) | AU772446B2 (xx) |
BR (1) | BR0008494A (xx) |
CA (1) | CA2364662C (xx) |
CO (1) | CO5140087A1 (xx) |
CZ (1) | CZ20013047A3 (xx) |
DE (1) | DE60015089T2 (xx) |
DK (1) | DK1157005T3 (xx) |
ES (1) | ES2230070T3 (xx) |
GC (1) | GC0000183A (xx) |
HK (1) | HK1044942B (xx) |
HR (1) | HRP20010604A2 (xx) |
HU (1) | HUP0200139A3 (xx) |
IL (2) | IL144851A0 (xx) |
JO (1) | JO2254B1 (xx) |
MA (1) | MA26773A1 (xx) |
MY (1) | MY122630A (xx) |
NO (1) | NO320099B1 (xx) |
NZ (1) | NZ513370A (xx) |
PL (1) | PL350428A1 (xx) |
PT (1) | PT1157005E (xx) |
RU (1) | RU2236402C2 (xx) |
SI (1) | SI1157005T1 (xx) |
TR (1) | TR200102489T2 (xx) |
WO (1) | WO2000050401A1 (xx) |
YU (1) | YU59901A (xx) |
ZA (1) | ZA200106371B (xx) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9928222D0 (en) | 1999-11-30 | 2000-01-26 | Univ Sheffield | Chiral catalysts for asymmetric acylation and related transformations |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
ATE470662T1 (de) * | 2000-11-20 | 2010-06-15 | Biovitrum Ab Publ | Piperazinylpyrazinverbindungen als agonisten oder antagonisten am serotonin-5ht-2-rezeptor |
SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6908935B2 (en) * | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US7176322B2 (en) * | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
AU2003263402A1 (en) * | 2002-09-20 | 2004-04-08 | Pfizer Products Inc. | Amide and sulfonamide ligands for the estrogen receptor |
KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
PE20090277A1 (es) * | 2007-04-24 | 2009-04-06 | Takeda Pharmaceutical | Derivados de piperidina como antagonistas de taquiquininas |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrのモジュレーター |
AU2008335440B2 (en) | 2007-12-07 | 2013-11-07 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
WO2009073757A1 (en) | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
US8299099B2 (en) | 2008-02-28 | 2012-10-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR modulators |
KR100943878B1 (ko) * | 2008-07-11 | 2010-02-24 | 오토스테크 주식회사 | 디지털방식 눈부심 방지 장치 및 그 제어 방법 |
US8592457B2 (en) * | 2008-10-30 | 2013-11-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
CN102712589B (zh) * | 2009-11-17 | 2015-05-13 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基-吡啶衍生物 |
WO2011127241A2 (en) | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
US8410107B2 (en) * | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
KR20160078997A (ko) | 2013-11-08 | 2016-07-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 카복시메틸피페리딘 유도체 |
WO2015073231A1 (en) | 2013-11-12 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
WO2016081556A1 (en) | 2014-11-18 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
JP7074673B2 (ja) | 2015-12-22 | 2022-05-24 | 武田薬品工業株式会社 | エンドソーマルgタンパク質共役受容体のトリパータイト・モジュレーター |
US20230348392A1 (en) | 2020-05-06 | 2023-11-02 | Bayer Aktiengesellschaft | Pyridine (thio)amides as fungicidal compounds |
JP2023529643A (ja) | 2020-06-04 | 2023-07-11 | バイエル、アクチエンゲゼルシャフト | 新規殺真菌剤としてのヘテロシクリルピリジン |
WO2023099445A1 (en) | 2021-11-30 | 2023-06-08 | Bayer Aktiengesellschaft | Bis(hetero)aryl thioether oxadiazines as fungicidal compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4174209A (en) * | 1978-06-19 | 1979-11-13 | Eli Lilly And Company | Herbicidal 1-alkyl-3-phenylpyridinium salts |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
EP1462450B1 (en) | 1993-12-29 | 2007-06-13 | MERCK SHARP & DOHME LTD. | Substituted morpholine derivatives and their use as therapeutic agents |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
ES2194937T3 (es) * | 1995-03-24 | 2003-12-01 | Takeda Chemical Industries Ltd | Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina. |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
-
2000
- 2000-02-15 CN CNB008042322A patent/CN1134417C/zh not_active Expired - Fee Related
- 2000-02-15 SI SI200030546T patent/SI1157005T1/xx unknown
- 2000-02-15 DK DK00909174T patent/DK1157005T3/da active
- 2000-02-15 CZ CZ20013047A patent/CZ20013047A3/cs unknown
- 2000-02-15 JP JP2000600984A patent/JP4068305B2/ja not_active Expired - Fee Related
- 2000-02-15 KR KR10-2001-7010731A patent/KR100437587B1/ko not_active IP Right Cessation
- 2000-02-15 AU AU31549/00A patent/AU772446B2/en not_active Ceased
- 2000-02-15 PL PL00350428A patent/PL350428A1/xx not_active Application Discontinuation
- 2000-02-15 EP EP00909174A patent/EP1157005B1/en not_active Expired - Lifetime
- 2000-02-15 AT AT00909174T patent/ATE280158T1/de not_active IP Right Cessation
- 2000-02-15 YU YU59901A patent/YU59901A/sh unknown
- 2000-02-15 RU RU2001125893/04A patent/RU2236402C2/ru not_active IP Right Cessation
- 2000-02-15 IL IL14485100A patent/IL144851A0/xx active IP Right Grant
- 2000-02-15 WO PCT/EP2000/001223 patent/WO2000050401A1/en active IP Right Grant
- 2000-02-15 CA CA002364662A patent/CA2364662C/en not_active Expired - Fee Related
- 2000-02-15 TR TR2001/02489T patent/TR200102489T2/xx unknown
- 2000-02-15 DE DE60015089T patent/DE60015089T2/de not_active Expired - Lifetime
- 2000-02-15 PT PT00909174T patent/PT1157005E/pt unknown
- 2000-02-15 BR BR0008494-8A patent/BR0008494A/pt not_active Application Discontinuation
- 2000-02-15 NZ NZ513370A patent/NZ513370A/xx unknown
- 2000-02-15 ES ES00909174T patent/ES2230070T3/es not_active Expired - Lifetime
- 2000-02-15 HU HU0200139A patent/HUP0200139A3/hu unknown
- 2000-02-16 US US09/505,359 patent/US6225316B1/en not_active Expired - Fee Related
- 2000-02-22 CO CO00012321A patent/CO5140087A1/es unknown
- 2000-02-22 MY MYPI20000647A patent/MY122630A/en unknown
- 2000-02-22 JO JO200015A patent/JO2254B1/en active
- 2000-02-23 GC GCP2000535 patent/GC0000183A/en active
- 2000-02-23 AR ARP000100756A patent/AR029616A1/es not_active Application Discontinuation
-
2001
- 2001-08-02 ZA ZA200106371A patent/ZA200106371B/en unknown
- 2001-08-09 IL IL144851A patent/IL144851A/en not_active IP Right Cessation
- 2001-08-14 HR HR20010604A patent/HRP20010604A2/hr not_active Application Discontinuation
- 2001-08-23 MA MA26301A patent/MA26773A1/fr unknown
- 2001-08-23 NO NO20014098A patent/NO320099B1/no unknown
-
2002
- 2002-08-27 HK HK02106317.1A patent/HK1044942B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1044942A1 (en) | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists | |
SI1035115T1 (en) | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | |
IL144611A0 (en) | Indole derivatives and their use as mcp-1 antagonists | |
IL155805A0 (en) | Novel sulfamides and their use as endothelin receptor antagonists | |
IL152700A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists | |
IL155634A0 (en) | 3-arylindole derivatives and their use as cb2 receptor agonists | |
MXPA03000923A (es) | Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano. | |
HUP0202202A3 (en) | Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof | |
SI1170288T1 (en) | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | |
PL356990A1 (en) | Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists | |
IL152701A0 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
EP1248607A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
AU8177801A (en) | 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists | |
PL350536A1 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor | |
PL351794A1 (en) | 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists | |
AUPQ570100A0 (en) | Beta-alanine derivatives and their use as receptor antagonists | |
EP1169042A4 (en) | DIBENZO-AZEPINE DERIVATIVES AS ANTAGONISTS OF THE ALPHA V INTEGRIN RECEPTOR | |
HK1049151A1 (zh) | 四氫化苯並吲衍生物、其製備方法和用作5-ht7受體拮抗劑的用途 | |
HUP0102531A3 (en) | Carboxy substituted carboxamide derivatives and their use as tachykinin receptor antagonists | |
AU8430701A (en) | Tetrahydrofuran derivatives and their use as nk-1 antagonists | |
AU2001230617A1 (en) | Beta-alanine derivatives and their use as receptor antagonists | |
HUP0201540A3 (en) | Serotomin and 5ht1a receptor antagonist phenoxypropylamine derivatives and use thereof | |
ZA9711305B (en) | Heterocyclic carboxylic acid derivatives their preparation and use as endothelin receptor antagonists | |
SI1003504T1 (en) | Indole derivatives and their use as mcp-1 antagonists | |
SI1187592T1 (sl) | Antagonisti alfa V integrinskega receptorja |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |